|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.50 USD | 0.00% |
|
0.00% | -0.23% |
| 13/01 | Avadel Pharmaceuticals Shareholders Approve Buyout by Alkermes | MT |
| 19/12 | Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from NASDAQ Biotechnology Index | CI |
| Capitalization | 2.11B 1.81B 1.68B 1.57B 2.93B 190B 3.14B 19.36B 7.61B 90.99B 7.91B 7.75B 334B | P/E ratio 2025 * |
78.5x | P/E ratio 2026 * | 27x |
|---|---|---|---|---|---|
| Enterprise value | 2.02B 1.73B 1.61B 1.5B 2.81B 182B 3.01B 18.56B 7.29B 87.22B 7.59B 7.43B 320B | EV / Sales 2025 * |
7.28x | EV / Sales 2026 * | 5.37x |
| Free-Float |
95.23% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Avadel Pharmaceuticals plc
| Current month | -0.23% | ||
| 1 month | +0.66% | ||
| 3 months | +53.57% | ||
| 6 months | +123.73% | ||
| Current year | -0.23% |
| 1 week | 21.4 |  | 21.56 |
| 1 month | 21.36 | | 21.68 |
| Current year | 21.4 | | 21.56 |
| 1 year | 6.38 | | 23.57 |
| 3 years | 6.38 | | 23.57 |
| 5 years | 6.38 | | 23.57 |
| 10 years | 6.38 | | 23.57 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 59 | 03/01/2019 |
Thomas McHugh
DFI | Director of Finance/CFO | 61 | 02/12/2019 |
Susan Rodriguez
COO | Chief Operating Officer | 62 | 13/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Gregory Divis
BRD | Director/Board Member | 59 | 03/06/2019 |
Peter Thornton
BRD | Director/Board Member | 61 | 01/07/2017 |
Geoffrey Glass
CHM | Chairman | 52 | 01/12/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | +172.15% | - | 2.11B | |
| +1.64% | +3.79% | +35.14% | +201.01% | 968B | |
| +2.61% | +2.65% | +47.63% | +20.53% | 505B | |
| -0.02% | -0.06% | +25.62% | +44.55% | 389B | |
| -0.85% | +4.30% | +28.16% | +17.49% | 367B | |
| -0.81% | +4.68% | +29.46% | +22.38% | 295B | |
| -1.21% | +1.63% | +10.02% | -2.31% | 271B | |
| -0.17% | +4.66% | +25.08% | +35.00% | 274B | |
| +1.71% | +11.03% | -37.20% | -15.73% | 263B | |
| -0.17% | +1.50% | +24.14% | +20.16% | 175B | |
| Average | -0.14% | +3.45% | +36.02% | +38.12% | 351.03B | |
| Weighted average by Cap. | -0.03% | +3.71% | +26.06% | +69.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 278M 238M 221M 206M 385M 25.03B 413M 2.55B 1B 11.98B 1.04B 1.02B 43.91B | 359M 307M 286M 267M 498M 32.36B 534M 3.29B 1.29B 15.48B 1.35B 1.32B 56.77B |
| Net income | 19.29M 16.51M 15.36M 14.32M 26.75M 1.74B 28.7M 177M 69.54M 832M 72.33M 70.84M 3.05B | 80.79M 69.18M 64.34M 59.98M 112M 7.28B 120M 741M 291M 3.48B 303M 297M 12.77B |
| Net Debt | -87.47M -74.9M -69.66M -64.94M -121M -7.88B -130M -802M -315M -3.77B -328M -321M -13.83B | -182M -156M -145M -135M -252M -16.38B -270M -1.67B -655M -7.83B -681M -667M -28.72B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/01/26 | 21.50 $ | 0.00% | 3,555,285 |
| 09/01/26 | 21.50 $ | +0.09% | 1,989,929 |
| 08/01/26 | 21.48 $ | -0.09% | 3,601,643 |
| 07/01/26 | 21.50 $ | 0.00% | 873,140 |
| 06/01/26 | 21.50 $ | 0.00% | 1,302,807 |
Delayed Quote Nasdaq, 13 January 2026 at 08:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AVDL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition